Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Mar;18(3):308-10.
doi: 10.1093/neuonc/nov329.

Next-generation sequencing of central nervous systems tumors: the future of personalized patient management

Leomar Y Ballester  1 , Adriana Olar  1 , Sinchita Roy-Chowdhuri  1
Affiliations
Editorial

Next-generation sequencing of central nervous systems tumors: the future of personalized patient management

Leomar Y Ballester et al. Neuro Oncol. 2016 Mar.
No abstract available

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Simplified view of current key molecular alterations in CNS neoplasms with diagnostic, prognostic, or predictive utility. The current landscape of important biomarkers in CNS neoplasms is rapidly changing as the importance of additional markers is established. Comprehensive molecular profiling with next-generation sequencing technologies will likely soon lead to more refined molecular classification of CNS tumors. Abbreviations: ATRT, atypical teratoid rhabdoid tumor; PXA, pleomorphic xanthoastrocytoma; SHH, sonic hedgehog pathway; WNT, wnt signaling pathway.
See this image and copyright information in PMC

Comment on

References

    1. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–1558. - PMC - PubMed
    1. Frattini V, Trifonov V, Chan JM, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet. 2013;45(10):1141–1149. - PMC - PubMed
    1. Brennan CW, Verhaak RGW, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–477. - PMC - PubMed
    1. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773. - PMC - PubMed
    1. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–2508. - PMC - PubMed

MeSH terms